North Carolina antibiotics maker Cempra has received a $10 million milestone payment from a Japanese drugmaker – indicative of the country’s need for a next-gen antibiotic. Toyama Pharmaceutical, a subsidiary of Fujifilm Holdings, owns exclusive rights to develop and commercialize Cempra’s new antibiotic, solithromycin, in Japan for respiratory tract infections like pneumonia. Though U.S. usage is number […]
Cempra (NASDAQ:CEMP) CEO Prabhavathi Fernandes speaks with urgency these days, particularly when discussing the antibiotics compounds her company plans for new drug applications in 2015. The Chapel Hill, North Carolina company spent last year seeking a large pharmaceutical company to take into late-stage development the two investigational antibiotics compounds treating drug-resistant bacteria. But Cempra ultimately […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Antibiotics developer Cempra (NASDAQ:CEMP) is now a public company with an initial public offering raising close to $50 million. But to pull off an IPO, the Chapel Hill, North Carolina pharmaceutical company needed to cut the targeted share price in half and sell more shares than it intended. Today’s offering of 8.4 million shares was […]